Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients was written by Uncu Ulu, Bahar;Dal, Mehmet Sinan;Yonal Hindilerden, Ipek;Akay, Olga Meltem;Mehtap, Ozgur;Buyukkurt, Nurhilal;Hindilerden, Fehmi;Gunes, Ahmet Kursad;Yigenoglu, Tugce Nur;Basci, Semih;Kizil Cakar, Merih;Yanardag Acik, Didar;Korkmaz, Serdal;Ulas, Turgay;Ozet, Gulsum;Ferhanoglu, Burhan;Nalcaci, Meliha;Altuntas, Fevzi. And the article was included in Journal of Chemotherapy (Abingdon, United Kingdom) in 2022.Application of 16506-27-7 The following contents are mentioned in the article:
The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-center real-life study, 61 R/R HL patients received i.v. doses of 1.8 mg/kg Bv on the first day plus 90 mg/m2 B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients’ median age at BvB initiation was 33 (range: 18-76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2-11). The overall and complete response rates were 82% and 68.9%, resp. After BvB initiation, the median follow-up was 14 mo, and one- and two-year overall survival rates were 85% and 72%, resp. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application of 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Application of 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem